Calyxo Launches Reverse Deflection CVAC System, Enhancing Kidney Stone Treatment

What's Happening?

Calyxo, Inc., a medical device company, has introduced a new feature called Reverse Deflection on its second-generation CVAC System, aimed at improving kidney stone treatment. This enhancement allows endourologists to perform the Steerable Ureteroscopic Renal Evacuation (SURE) procedure with greater control and familiarity, using their preferred steering mode. The launch was announced at the 42nd World Congress of Endourology and Uro-Technology (WCET) 2025, where 15 clinical presentations highlighted the system's safety and efficacy. The Reverse Deflection option addresses the cognitive load on physicians by providing an intuitive navigation experience. The CVAC System, FDA-cleared in 2024, offers a minimally invasive approach for kidney stone clearance, using irrigation and vacuum aspiration to remove stone fragments during and after laser lithotripsy.

Why It's Important?

The introduction of the Reverse Deflection CVAC System is significant for the medical community, particularly in the field of endourology. It represents a shift towards more intuitive and efficient kidney stone treatments, potentially reducing healthcare consumption events such as emergency department visits and hospitalizations. The system's ability to achieve high stone clearance rates and reduce residual stone volume could lead to better long-term outcomes for patients. This innovation may also lower healthcare costs associated with kidney stone disease, which are projected to reach $4.1 billion annually by 2030. By providing a more effective treatment option, Calyxo's technology could improve patient care and set a new standard in the industry.

What's Next?

Following the launch, Calyxo is likely to focus on expanding the adoption of the Reverse Deflection CVAC System among endourologists. The company may also continue to gather and present clinical data to further validate the system's efficacy and safety. As more healthcare providers adopt this technology, there could be a shift towards using standardized volumetric metrics like Residual Stone Volume (RSV) to guide treatment decisions. This could lead to broader changes in clinical practice and potentially influence guidelines for kidney stone management. Additionally, Calyxo may explore further enhancements to the CVAC System to maintain its competitive edge in the market.